Form 4: Silexion Director Peled Acquires Shares, Options

Silexion Therapeutics Director Amnon Peled acquired 661 ordinary shares and 780 stock options, with both awards vesting on February 9, 2026.

Summary

• Director Amnon Peled was granted 661 ordinary shares in the form of Restricted Stock Units (RSUs) on February 9, 2025, as compensation for board service.
• Peled also received 780 stock options to purchase ordinary shares on February 9, 2025, with an exercise price of $18.9 per share.
• Both the RSUs and stock options are scheduled to vest in full on February 9, 2026, contingent upon Peled's continued service as a director.
• The reported number of ordinary shares and stock options, as well as the option exercise price, have been retroactively adjusted to reflect a 1-for-15 reverse share split effected by Silexion Therapeutics Corp on July 29, 2025.

Sentiment

Score: 4

Explanation: While the director's acquisition of equity can be seen as a positive signal of confidence, the context of a recent 1-for-15 reverse share split significantly dampens the overall sentiment, as reverse splits are typically indicative of poor stock performance and underlying company challenges.

Positives

• A director's acquisition of shares and options, even as compensation, can signal alignment of interests with shareholders and confidence in the company's future.

Negatives

• The company effected a 1-for-15 reverse share split on July 29, 2025, which is often a negative indicator suggesting a low stock price and potential challenges in meeting listing requirements.

Risks

• The 1-for-15 reverse share split indicates that the company's stock price has faced significant downward pressure, which could reflect underlying operational or financial challenges.
• The vesting of RSUs and stock options is subject to the reporting person's continued service, meaning the benefits are not guaranteed if service ceases.

Future Outlook

The granted RSUs and stock options are set to vest on February 9, 2026, contingent on the director's continued service, aligning future compensation with ongoing company performance and board participation.

Management Comments

• The ordinary shares underlying RSUs were granted as consideration for the Reporting Person's service on the Issuer's board of directors.
• The shares subject to this award vest in full on the first anniversary of the grant date (i.e., on February 9, 2026), subject to the Reporting Person's continued service through such date.
• The number of ordinary shares and options, and the option exercise price, have been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for publicly traded companies. The reverse share split, however, is a more significant event, often seen in industries like biotechnology or emerging tech where companies may experience volatility or need to maintain minimum share prices for exchange listing, indicating potential challenges in market valuation.

Corporate Governance

Related Party Transactions

• Grant of 661 ordinary shares (RSUs) to Director Amnon Peled as compensation for board service.
• Grant of 780 stock options to Director Amnon Peled as compensation for board service.

Stakeholder Impact

• Shareholders: The reverse share split impacts the number of shares held and their per-share value, potentially affecting market perception and liquidity. The equity grants to a director represent a form of dilution but also align management incentives.
• Employees: No direct impact mentioned, but the reverse split could signal broader company performance issues that might affect employee morale or future compensation plans.

Next Steps

• Monitoring the vesting of the granted RSUs and stock options on February 9, 2026, subject to the director's continued service.

Key Dates

Recommendation

The director's acquisition of shares and options could signal confidence, but the recent 1-for-15 reverse share split suggests the company has faced significant stock price challenges. Investors should hold and monitor future performance and strategic developments, particularly regarding the underlying reasons for the reverse split and its impact on the company's long-term viability and market perception.

Keywords

Silexion Therapeutics, SLXN, Form 4, insider transaction, stock options, RSU, reverse stock split, director compensation, equity grants